RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort

por O’Sullivan, J. M., Taylor, J., Gerds, A., Buckley, S., Harrison, C. N., Oh, S., List, A. F., Howard, K., Dreau, H., Hamblin, A., Mead, A. J.
Publicado 2023

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/A...

por Harrison, C N, Gregory, W, Hudson, G Vaughan, Devereux, S, Goldstone, A H, Hancock, B, Winfield, D, MacMillan, A K, Hoskin, P, Newland, A C, Milligan, D, Linch, D C
Publicado 1999

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

por Harrison, C N, Vannucchi, A M, Kiladjian, J-J, Al-Ali, H K, Gisslinger, H, Knoops, L, Cervantes, F, Jones, M M, Sun, K, McQuitty, M, Stalbovskaya, V, Gopalakrishna, P, Barbui, T
Publicado 2016

Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

por Harrison, C N, Vannucchi, A M, Kiladjian, J-J, Al-Ali, H K, Gisslinger, H, Knoops, L, Cervantes, F, Jones, M M, Sun, K, McQuitty, M, Stalbovskaya, V, Gopalakrishna, P, Barbui, T
Publicado 2017

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS

por Kiladjian, J.-J., Tefferi, A., Passamonti, F., Vannucchi, A., Talpaz, M., Cervantes, F., Harrison, C. N., Mesa, R. A., Mascarenhas, J., Schaap, N., Verstovsek, S., Devos, T., Rose, S., Zhang, J., Sy, O., Pardanani, A.
Publicado 2022

P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO...

por Mascarenhas, J., Harrison, C. N., Kiladjian, J.-J., Komrokji, R. S., Koschmieder, S., Vannucchi, A. M., Berry, T., Redding, D., Sherman, L., Dougherty, S., Peng, L., Sun, L., Huang, F., Wan, Y., Feller, F. M., Rizo, A., Verstovsek, S.
Publicado 2022

P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREAT...

por Gupta, V., Yacoub, A., Verstovsek, S., Mesa, R. A., Harrison, C. N., Barosi, G., Kiladjian, J.-J., Deeg, H. J., Fazal, S., Foltz, L., Mattison, R. J., Miller, C. B., Parameswaran, V., Hernandez, C., Zhang, J., Talpaz, M.
Publicado 2022

P1033: A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)

por Palandri, F., Ross, D. M., Cochrane, T., Tate, C., Lane, S. W., Larsen, S. R., Gerds, A. T., Halpern, A. B., Shortt, J., Rossetti, J. M., Pettit, K. M., Liang, J., Mead, A., Marchetti, M., Vannucchi, A., Wilson, A., Göthert, J. R., Hanna, M., Jones, A., Peppe, J., Natsoulis, G., McClure, T., Hong, W.-J., Stevenson, W. S., Harrison, C. N., Talpaz, M., Vianelli, N., Rienhoff, H. Y.
Publicado 2022

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neopla...

por Jovanovic, J V, Ivey, A, Vannucchi, A M, Lippert, E, Oppliger Leibundgut, E, Cassinat, B, Pallisgaard, N, Maroc, N, Hermouet, S, Nickless, G, Guglielmelli, P, van der Reijden, B A, Jansen, J H, Alpermann, T, Schnittger, S, Bench, A, Tobal, K, Wilkins, B, Cuthill, K, McLornan, D, Yeoman, K, Akiki, S, Bryon, J, Jeffries, S, Jones, A, Percy, M J, Schwemmers, S, Gruender, A, Kelley, T W, Reading, S, Pancrazzi, A, McMullin, M F, Pahl, H L, Cross, N C P, Harrison, C N, Prchal, J T, Chomienne, C, Kiladjian, J J, Barbui, T, Grimwade, D
Publicado 2013